Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
This phase I study evaluated a Gene Mediated Cytotoxic Immunotherapy approach for malignant
gliomas, including glioblastoma multiforme and anaplastic astrocytoma. The purpose of this
study was to assess the safety and feasibility of delivering an experimental approach called
GliAtak which uses AdV-tk, an adenoviral vector containing the Herpes Simplex thymidine
kinase gene, plus an oral anti-herpetic prodrug, valacyclovir, in combination with standard
of care radiation.